SARESA

Serial Number 78357601
602

Registration Progress

Application Filed
Jan 26, 2004
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: SARESA
Previous Owner: MDS Inc.
Classes: 005, 042

Trademark Image

SARESA

Basic Information

Serial Number
78357601
Filing Date
January 26, 2004
Abandonment Date
June 9, 2006
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Jul 6, 2006
Classes
005 042

Rights Holder

MDS Inc.

03
Address
100 International Boulevard
Toronto M9W 6J6
CA

Ownership History

MDS Inc.

Original Applicant
03
Toronto CA

Legal Representation

Attorney
John A. Clifford

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

17 events
Date Code Type Description Documents
Jul 6, 2006 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
Jul 6, 2006 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Dec 8, 2005 CNSI S INQUIRY AS TO SUSPENSION MAILED Loading...
Dec 8, 2005 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Jun 7, 2005 CNSL S LETTER OF SUSPENSION MAILED Loading...
Jun 7, 2005 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jun 1, 2005 DOCK D ASSIGNED TO EXAMINER Loading...
May 31, 2005 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 28, 2005 ACEC I AMENDMENT FROM APPLICANT ENTERED Loading...
Feb 25, 2005 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 21, 2005 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 8, 2005 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 25, 2005 MAIL I PAPER RECEIVED Loading...
Mar 7, 2005 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 24, 2004 CNRT F NON-FINAL ACTION MAILED Loading...
Aug 18, 2004 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 4, 2004 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of radioimmune diseases, namely radioimmunetherapeutics; pharmaceutical preparations in the nature of drug antibody and toxin-antibody conjugates for the purpose of removing and fighting toxins in the body; pharmaceutical preparations in the nature of targeted therapeutics for the diagnosis, therapy and/or prevention of human conditions or disease, namely for use in the treatment of cancer, specifically blood borne cancers and solid tumors;pharmaceutical preparations in the nature of drug delivery agents consisting compounds that facilitate delivery of a wide range of pharmaceuticals comprised of proteins,peptides, peptidomimetics, lipids, carbohydrates, nucleic acids, aptamers, and/or synthetic organic molecules, that selectively bind to any human or bacterial cell, any cell type, any fungus, any virus, any human pathogen, or any component of the above,including fragments and semi-synthetic derivatives
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Pharmaceutical drug development services; scientific research in the field of pharmaceuticals; medical and scientific research, namely conducting clinical trials of pharmaceuticals
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 042